| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04539041 | Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy | PHASE1 | COMPLETED | 59 | — | — | Feb 16, 2021 | Oct 17, 2024 | Dec 24, 2025 | 12 | United States, Canada +2 |
Adverse events will be collected at clinical visits and other contacts. All abnormalities from safety assessments (physical exams and neurological exams and clinical safety labs) considered clinically significant will be recorded as adverse events
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire that prospectively assesses Suicidal Ideation and Suicidal Behavior. The C-SSRS must be administered at visits. If, at any time after "screening and/or baseline" version, the score is "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS or "yes" on any item of the Suicidal Behavior section, the participant must be referred to a mental health care professional for further assessment and/or treatment.
CSF safety labs measure levels of proteins, glucose, lactate and white blood cell counts with differential indicating infections.
| Arm | Type | Description |
|---|---|---|
| Cohort A NIO752 | EXPERIMENTAL | 4 injections of NIO752 at dose A |
| Cohort B NIO752 | EXPERIMENTAL | 4 injections of NIO752 at dose B |
| Placebo | PLACEBO_COMPARATOR | 4 injections of placebo |
| Cohort C NIO752 | EXPERIMENTAL | 4 injections of NIO752 at dose C |
| Cohort D NIO752 | EXPERIMENTAL | 4 injections of NIO752 at dose D |
| Cohort E NIO752 | EXPERIMENTAL | 4 injections of NIO752 at dose E |
| Name | Type | Description |
|---|---|---|
| antisense oligonucleotide | DRUG | solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels |
| placebo | DRUG | placebo for each dose level |
Inclusion Criteria: 1. Signed informed consent 2. Between 40 to 75 years old (inclusive) 3. Have PSP diagnosed for less than 5 years with a current classification of probable PSP Richardson syndrome, a progressive supranuclear palsy rating scale (PSPRS) score \< 40 and MOCA score \>17 at screening ...